The popularity of weight loss injections like Mounjaro, Wegovy, and Ozempic has soared, but a worrying trend has emerged after 10 deaths raised questions about their safety. UK health officials are investigating serious side effects, especially pancreatitis, urging users to be aware and report issues. These drugs, meant for Type-2 diabetes, are now under scrutiny for their unexpected risks.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has received over 560 reports of pancreatitis, a condition causing intense stomach pain that can spread to the back, among people using GLP-1 injections. With these drugs gaining fame for weight loss, thanks to celebrity endorsements, the MHRA is checking if genetics make some users more likely to develop this issue. They’re asking anyone hospitalized with pancreatitis to use the Yellow Card scheme to report it.
To learn more, the MHRA is collaborating with Genomics England on a Biobank study, using saliva samples to explore genetic links to pancreatitis (MailOnline). Dr. Alison Cave, MHRA’s chief safety officer, told MailOnline that genetic testing could prevent nearly a third of side effects, potentially saving the NHS £2.2 billion a year in hospital costs. This could lead to safer prescribing, helping patients avoid dangerous reactions.
The MHRA has linked 181 pancreatitis cases to one injection’s ingredient and 113 cases to two others, though the deaths aren’t directly tied to the drugs yet. Other side effects, like nausea, diarrhea, and constipation, are also common, and users should talk to their doctors about any concerns. Reporting issues helps build a clearer safety picture for everyone.
A Novo Nordisk spokesperson told LADbible that patient safety comes first, with risks outlined in product guides, and they support ongoing studies. A Lilly spokesperson told LADbible that Mounjaro’s information notes pancreatitis as a rare side effect, advising doctor consultations. As research continues, users should stay informed, report problems, and work with healthcare providers to use these drugs safely.
